Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis

被引:54
作者
Gensch, Christoph [1 ]
Clever, Yvonne [1 ]
Werner, Christian [1 ]
Hanhoun, Milad [1 ]
Boehm, Michael [1 ]
Laufs, Ulrich [1 ]
机构
[1] Univ Klinikum Saarlandes, Klin Innere Med 3, D-66421 Homburg, Germany
关键词
endothelial progenitor cells; prostaglandin; apoptosis; angiogenesis; nitric oxide;
D O I
10.1016/j.yjmcc.2006.12.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone marrow derived endothelial progenitor cells (EPC) improve endothelial function and neoangiogenesis. Prostaglandin E1 (PGE1) is used for the treatment of patients with peripheral artery disease (PAD). However, the molecular effects are only partially understood. Treatment of C57/B16 mice with PGE1, 10 mu g/kg BW increased the number of circulating Sca-I/VEGFR-2 positive EPC in the blood compared to vehicle (122 +/- 7% and 119 +/- 6% after 10 and 20 days). EPC in the bone marrow were upregulated to 125 +/- 11% (10 days) and 142 +/- 15% (20 days). PGE1 increased DiLDL/Lectin positive spleen-derived EPC to 170 +/- 20% and 174 +/- 14% after 10 and 20 days. Treatment with PGE1 enhanced in-vivo neoangiogenesis by 2-fold (disk assay, 218 +/- 27%). PGE1 enhanced the SDF-1 induced migratory capacity per number of EPC to 140 +/- 11%, 146 +/- 22% and 160 +/- 16% after 10, 14 and 20 days. Greater migratory capacity was associated with upregulation of expression of telomere repeat-binding factor (TRF2). EPC of PGE1-treated mice were characterized by reduced apoptosis. Similarly, PGE1 prevented H2O2-induced apoptosis in cultured human EPC. The effect is mediated by PI3-kinase. The effects of PGE1 on EPC were completely prevented by co-treatment with the NO-inhibitor L-NAME, 50 mg kg(-1) p.o. Treatment with the prostaglandin 12 derivative iloprost (10 mu g/kg BW, 20 days) did not alter EPC numbers or function. Physical exercise is the basis of the treatment of patients with PAD. Voluntary running increased EPC numbers in mice. Treatment with PGE1 resulted in an additional increase of Sca-1/VEGFR-2- and DiLDL/lectin positive EPC as well as migration. n = 10-24 for all groups, all effects p<0.05. In summary, prostaglandin E1 increases the number of EPC in the blood and the bone marrow in mice. The effect is additive to physical exercise, depends on nitric oxide and is characterized by reduction of PI3-kinase mediated apoptosis. PGE1-mediated upregulation of EPC is associated with improved EPC function and enhanced angiogenesis. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:670 / 677
页数:8
相关论文
共 37 条
[1]   Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia [J].
Adams, V ;
Lenk, K ;
Linke, A ;
Lenz, D ;
Erbs, S ;
Sandri, M ;
Tarnok, A ;
Gielen, S ;
Emmrich, F ;
Schuler, G ;
Hambrecht, R .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (04) :684-690
[2]   Mobilizing endothelial progenitor cells [J].
Aicher, A ;
Zeiher, AM ;
Dimmeler, S .
HYPERTENSION, 2005, 45 (03) :321-325
[3]   Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells [J].
Aicher, A ;
Heeschen, C ;
Mildner-Rihm, C ;
Urbich, C ;
Ihling, C ;
Technau-Ihling, K ;
Zeiher, AM ;
Dimmeler, S .
NATURE MEDICINE, 2003, 9 (11) :1370-1376
[4]   PGE1 and other prostaglandins in the treatment of intermittent claudication:: A meta-analysis [J].
Amendt, K .
ANGIOLOGY, 2005, 56 (04) :409-415
[5]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[6]   Circulating hematopoietic progenitor cells in runners [J].
Bonsignore, MR ;
Morici, G ;
Santoro, A ;
Pagano, M ;
Cascio, L ;
Bonanno, A ;
Abate, P ;
Mirabella, F ;
Profita, M ;
Insalaco, G ;
Gioia, M ;
Vignola, AM ;
Majolino, I ;
Testa, U ;
Hogg, JC .
JOURNAL OF APPLIED PHYSIOLOGY, 2002, 93 (05) :1691-1697
[7]   Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV [J].
Creutzig, A ;
Lehmacher, W ;
Elze, M .
VASA-JOURNAL OF VASCULAR DISEASES, 2004, 33 (03) :137-144
[8]   HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway [J].
Dimmeler, S ;
Aicher, A ;
Vasa, M ;
Mildner-Rihm, C ;
Adler, K ;
Tiemann, M ;
Rütten, H ;
Fichtlscherer, S ;
Martin, H ;
Zeiher, AM .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (03) :391-397
[9]   ILOPROST - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN PERIPHERAL VASCULAR-DISEASE, MYOCARDIAL-ISCHEMIA AND EXTRACORPOREAL-CIRCULATION PROCEDURES [J].
GRANT, SM ;
GOA, KL .
DRUGS, 1992, 43 (06) :889-924
[10]   PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells [J].
Haider, DG ;
Bucek, RA ;
Giurgea, AG ;
Maurer, G ;
Glogar, H ;
Minar, E ;
Wolzt, M ;
Mehrabi, MR ;
Baghestanian, M .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 289 (05) :H2066-H2072